ArticleBritish journal of haematology2021
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
Article in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Academic Performance of Children With Sickle Cell Disease in the United States: A Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Neurocognitive gains among Ugandan children with sickle cell anemia on hydroxyurea: 18-month interim trial results.Blood advances · 2025Trial
- Quantifying dilated perivascular spaces in children with sickle cell disease.Pediatric blood & cancer · 2024Trial
- A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.Blood advances · 2023Trial
- Hydroxyurea for Ugandan Children with Sickle Cell Anemia.The New England journal of medicine · 2026Article
- Sustainment of Hydroxyurea Adherence in Patients With Sickle Cell Disease.JAMA network open · 2026Observational
- Mechanism-informed transition from pediatric to adult care in sickle cell disease: a case study.BMC health services research · 2026Article
- Article
- Regional brain age is decreased in children with sickle cell anemia.Blood advances · 2026Article
- Cerebral blood flow trajectories in paediatric sickle cell anaemia by age, region, and treatment associations.British journal of haematology · 2026Article
- Adapting a school readiness intervention for children with sickle cell disease: an intervention mapping for adaptation approach.Frontiers in public health · 2026Article
- Chronic Hydroxyurea Therapy in Children with Sickle Cell Anemia: Mechanisms of Action, Systemic Effects, and Long-Term Safety.Journal of clinical medicine · 2025Review
- Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.Blood global hematology · 2025Article
- Hydroxyurea Therapy in Sickle Cell Disease: Evaluating Healthcare Costs and Utilization in a Brazilian Tertiary Setting.Blood global hematology · 2025Article
- Statewide Academic Performance of High School Students With Sickle Cell Disease.Pediatric blood & cancer · 2025Article
- Academic Proficiency in Ugandan Children With Sickle Cell Anemia: A Cross-Sectional Study.Pediatric blood & cancer · 2025Article
- A clinical evaluation program to monitor neurocognitive risk in children and adolescents with sickle cell disease.The Clinical neuropsychologist · 2025Article
- Utility of caregiver signaling questions to detect neurocognitive impairment in children with sickle cell disease.Blood advances · 2025Article
- Caregiver and provider perspectives on developmental services for children with sickle cell disease: a mixed methods analysis.Frontiers in pediatrics · 2025Article
- Perinatal risk factors and neurocognitive outcomes in children and adolescents with sickle cell disease.Pediatric blood & cancer · 2024Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Neurocognitive impairment is common in sickle cell disease (SCD) and is associated with significant functional limitations. In a cross-sectional analysis, we examined the association between hydroxyurea (HU) treatment and neurocognitive functioning from school-age to young adulthood in individuals with SCD. A total of 215 patients with HbSS/HbSβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.